1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity

 
• By Emily Hayes

Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.

Bristol-Myers-Squib_685347493_1200.jpg

With Bristol-Myers Squibb Co.'s sales of its PD-1 inhibitor Opdivo still strong but slipping behind Merck & Co. Inc.'s competing Keytruda, the company is under pressure to acquire new assets as a backup plan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.

J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200

 
• By Alaric DeArment

The drug maker presented data from two cohorts of a pivotal Phase IIb study in NMIBC. Cost and ease of administration offer the potential to benefit the drug commercially.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.